Citigroup’s Iterum Therapeutics ITRM Stock Holding History

Citigroup’s Portfolio ITRM Stock Details ITRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,667	Closed	-$8K	–	6077
2022 Q2	$8K	Buy	2,667 +2,580	+2,966%	+$9.65K	﹤0.01%	5446
2022 Q1	$0	Buy	+87	New	+$503	﹤0.01%	6469

Other funds holding ITRM

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup's ITRM Position: Q3 2022 in Review

Citigroup sold out of Iterum Therapeutics (ITRM) in Q3 2022, closing a stake of 2,667 shares — an estimated $8K sold.

Citigroup first reported a position in ITRM in Q1 2022 and held it in 2 quarters. The position peaked at $8K in Q2 2022. 25 funds tracked by Wall St. Rank hold ITRM as of Q3 2022.

Citigroup reported no remaining Iterum Therapeutics position as of Q3 2022 after selling out during the quarter.
Citigroup sold 2,667 Iterum Therapeutics shares in Q3 2022, an estimated $8K.
Citigroup first reported a position in Iterum Therapeutics in Q1 2022 and held it in 2 quarters.
Citigroup's Iterum Therapeutics position peaked at $8K in Q2 2022.
25 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2022.

Based on Citigroup's 13F filing for Q3 2022, filed 10 Nov 2022.